Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile InfectionPRNewsWire • 11/02/23
Acurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business UpdatePRNewsWire • 10/25/23
Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific ConferencesPRNewsWire • 10/19/23
Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile InfectionPRNewsWire • 10/02/23
Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific CongressPRNewsWire • 09/12/23
Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023PRNewsWire • 08/22/23
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business UpdatePRNewsWire • 08/14/23
Acurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business UpdatePRNewsWire • 07/24/23
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023PRNewsWire • 06/20/23
Acurx Pharmaceuticals to Participate in the Maxim Group LLC Virtual Healthcare Conference on Tuesday, June 20, 2023 to Thursday, June 22, 2023 at 9 am ETPRNewsWire • 06/15/23
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct OfferingPRNewsWire • 05/16/23
Acurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business UpdatePRNewsWire • 05/12/23
Acurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business UpdatePRNewsWire • 05/05/23
Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific ConferencePRNewsWire • 04/19/23
FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific ConferencePRNewsWire • 04/11/23
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdatePRNewsWire • 03/16/23
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business UpdatePRNewsWire • 03/06/23
CEO Spotlight: Acurx Pharmaceuticals CEO Confident His Phase 2b Ibezapolstat Drug Candidate Can Earn Front-Line Designation to Treat C. difficileNewsfile Corp • 02/07/23
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023PRNewsWire • 01/16/23
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business UpdatePRNewsWire • 11/14/22